No room for statins in the quest for survival benefits in small cell lung cancer

Targeted agents and immunotherapy are revolutionizing the continuum of care for patients suffering from non-small cell lung cancer (NSCLC) (1). On the other hand, SCLC management remains a critical and disappointing issue. The definition of a “fast, hungry and unstable” disease provided by Christine Hann and Charles Rudin more than 10 years ago (2) is unfortunately still applicable.